The European Commission has cleared €23 million of proposed funding for Novartis Italy to develop vaccines in developing countries. After its assessment for R&D&I aid (research, development and innovation), the Commission has found that the support addresses a genuine market failure and stimulates research in the EU. Novartis’ project will create innovative vaccines at affordable prices. The project is also supported by the Gates Foundation and is expected to incur €76.9 million in R&D over five years.
Full content: EC Press Release
Related content: Revision of the EU Competition Rules on Cooperation in Research & Development and Production: Scope for Further Improvement (Axel Gutermuth, Arnold & Porter)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Apple Faces Contempt Hearings Over App Store Reforms
May 19, 2024 by
CPI
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI